Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis

Autoimmunity ◽  
2009 ◽  
Vol 43 (2) ◽  
pp. 172-178 ◽  
Author(s):  
P. Serrano-Fernández ◽  
S. Möller ◽  
R. Goertsches ◽  
H. Fiedler ◽  
D. Koczan ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Drug Therapy ◽  
Time Course

scholarly journals Time of interferon-β 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients

2007 ◽  
Vol 13 (9) ◽  
pp. 1138-1145 ◽  
Author(s):  
T. Kümpfel ◽  
M. Schwan ◽  
Th. Pollmächer ◽  
A. Yassouridis ◽  
M. Uhr ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Time Course ◽  
Group A ◽  
Systemic Side Effects ◽  
Plasma Hormone ◽  
Group B ◽  
Acute Changes ◽  
Multiple Sclerosis Patients ◽  
Time Point

During initiation of interferon-beta (IFN-β) therapy, many multiple sclerosis (MS) patients experience systemic side effects which may depend on the time point of IFN-β injection. We investigated the time course of plasma hormone-, cytokine- and cytokine-receptor concentrations after the first injection of IFN-β either at 8.00 a.m. (group A) or at 6.00 p.m. (group B) and quantified clinical side effects within the first 9 h in 16 medication free patients with relapsing-remitting MS. This investigation was repeated after 6-month IFN-β therapy. Plasma ACTH and cortisol concentrations followed their physiological rhythms, with lower levels in the evening compared to the morning, but raised earlier and stronger in group B after IFN-β administration. IFN-β injection in the evening led to a prompter increase of plasma IL-6 concentrations and temperature during the first hours and correlated to more intense clinical side effects compared to group A. Plasma IL-10 concentrations increased more in group A compared to group B, but sTNF-RI and sTNF-RII concentrations raised 7 h after IFN-β injection only in group B. Acute effects on plasma hormone and cytokine concentrations adapted after 6-month IFN-β treatment, while diurnal variations were still present. Baseline sTNF-RII concentrations were elevated after 6-month IFN-β therapy only in group A. Our results show that time point of IFN-β injection has differential effects on acute changes of plasma hormone and cytokine concentrations and is related to systemic side effects. This may have implications on the tolerability and effectiveness of IFN-β therapy. Multiple Sclerosis 2007; 13: 1138—1145. http://msj.sagepub.com

Time-course of interleukin-2 receptor expression in interferon beta-treated multiple sclerosis patients

1998 ◽  
Vol 84 (2) ◽  
pp. 213-217 ◽  
Author(s):  
Anna M Ferrarini ◽  
Susanna Sivieri ◽  
Pietro Bulian ◽  
Mario Buttarello ◽  
Giovanni Biasi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Time Course ◽  
Interferon Beta ◽  
Interleukin 2 ◽  
Receptor Expression ◽  
Interleukin 2 Receptor ◽  
Multiple Sclerosis Patients

Uveitis associated with multiple sclerosis

2008 ◽  
Vol 14 (3) ◽  
pp. 415-417 ◽  
Author(s):  
Julie Le Scanff ◽  
Pascal Sève ◽  
Christel Renoux ◽  
Christiane Broussolle ◽  
Christian Confavreux ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Time Course ◽  
Clinical Spectrum ◽  
Significant Difference

Our study aimed to determine the frequency of uveitis among MS patients through the Lyon MS Database and compare the clinical spectrum and time course of MS in patients with or without uveitis. Twenty-eight patients with uveitis were detected. The prevalence of uveitis in our population was 0.65% (28/4300). Uveitis preceded onset of MS in 46% of the patients; it occurred simultaneously or after MS, in 18% and 36% of the cases, respectively. The topography and timing of uveitis were not associated with any significant difference in MS course and prognosis. There was no difference in the course and prognosis in patients with or without uveitis. Multiple Sclerosis 2008; 14: 415—417. http://msj.sagepub.com

scholarly journals PHS51 Hospital Stays of Multiple Sclerosis Patients in Germany – Reasons, Frequencies, Duration and Impact on Drug Therapy

2012 ◽  
Vol 15 (7) ◽  
pp. A527
Author(s):  
A. Seiffert ◽  
F.W. Dippel ◽  
G. Sommer ◽  
B. Holz ◽  
M. Trottmann
Keyword(s):  
Multiple Sclerosis ◽  
Drug Therapy ◽  
Hospital Stays ◽  
Multiple Sclerosis Patients

scholarly journals PND24 Cost of Symptomatic Drug Therapy in Multiple Sclerosis

2011 ◽  
Vol 14 (7) ◽  
pp. A321
Author(s):  
E. Fogarty ◽  
L. Tilson ◽  
M. Barry
Keyword(s):  
Multiple Sclerosis ◽  
Drug Therapy

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients

2005 ◽  
Vol 11 (6) ◽  
pp. 626-634 ◽  
Author(s):  
R A Rudick ◽  
G R Cutter ◽  
M Baier ◽  
B Weinstock-Guttman ◽  
M K Mass ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Drug Therapy ◽  
Natural History ◽  
Treatment Effect ◽  
Phase Iii ◽  
Disease Modifying ◽  
Multiple Sclerosis Patients

Two methods were used to estimate the long-term impact of disease-modifying drug therapy (DMDT) in patients with relapsing multiple sclerosis (MS) who completed a placebo-controlled, randomized clinical trial of interferon beta-1a (IFNβ-1a). The study cohort consisted of patients with ambulatory relapsing MS who had previously participated in a placebo-controlled clinical trial for two years. At its end, patients were managed in an unstructured fashion by their neurologists and re-evaluated at an average of 6.1 years after the end of the trial. Follow-up evaluation was obtained for 93% of the 172 eligible patients. Because study inclusion criteria required that all patients have an Expanded Disability Status Scale (EDSS) score of ≤3.5 at entry, disability progression at follow-up was defined as EDSS≥6.0. Two methods were used to estimate the expected proportions that reached EDSS≥6.0 at follow-up. Estimates were compared with observed proportions. Method 1 used progression rates observed during the two-year phase III clinical trial and the percentage of time that patients were on DMDT during the follow-up period. Method 2 used progression rates from a natural history comparison group of relapsing-remitting MS patients. At the eight-year follow-up, 42.0% of the original placebo patients and 29.1% of the original IFNβ-1a patients reached an EDSS ≥ 6.0, an observed treatment effect of approximately 30%. Using method 1, it was estimated that 36.3% of the original placebo patients and 27.6% of the original IFNβ-1a patients should have reached an EDSS ≥ 6.0. Use of the natural history control group (method 2) predicted less plausible outcomes. Estimated proportions of patients reaching the endpoint were 63.3% for the original placebo group and 55.8% for the original IFNβ-1a group. Treatment effect sizes of 75-90% would be required to match estimates from method 2 with the observed outcome. The paucity of data on the long-term treatment of patients with MS may be aided by applying these or similar methods to vigorously followed cohorts of patients.

scholarly journals Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects

2017 ◽  
Vol 10 (4) ◽  
pp. 191-209 ◽  
Author(s):  
Max J. Hilz ◽  
Ruihao Wang ◽  
Carmen de Rojas Leal ◽  
Mao Liu ◽  
Francesca Canavese ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Time Course ◽  
Low Frequency ◽  
Autonomic Modulation ◽  
Autonomic Changes ◽  
Relapsing Remitting ◽  
Multiple Sclerosis Patients ◽  
Post Hoc ◽  
Relapsing Remitting Multiple Sclerosis

Background: Fingolimod slows heart rate (HR) due to vagomimetic effects and might cause additional cardiovascular autonomic changes. While the time course of HR changes is well described, the extent and course of cardiovascular autonomic changes upon fingolimod initiation has not yet been evaluated. This study, therefore, intended to assess cardiovascular autonomic changes during the first 6 h after fingolimod initiation. Methods: In 21 patients with relapsing-remitting multiple sclerosis (RRMS), we recorded respiration (RESP), electrocardiographic RR interval (RRI), systolic and diastolic blood pressure (BPsys, BPdia) at rest, before and 0.5, 1, 2, 3, 4, 5, and 6 h after fingolimod initiation. We calculated parameters of total autonomic modulation [RRI standard deviation (RRI-SD), RRI coefficient of variation (RRI-CV), RRI-total powers], mainly sympathetic cardiac modulation [RRI low frequency (LF) powers], sympathetic BP modulation (BPsys-LF powers), parasympathetic modulation [square root of the mean squared difference of successive RRIs (RMSSD), RRI high frequency (HF) powers], sympatho-vagal cardiac balance (RRI-LF/HF ratios), and baroreflex sensitivity (BRS). We compared parameters between the eight measurements [analysis of variance (ANOVA) or Friedman test with post-hoc analysis; significance: p < 0.05]. Results: After fingolimod initiation, RESP, BPsys, and BPsys-LF powers remained unchanged while RRIs, RRI-CV, RRI-SD, RRI-total powers, RRI-LF powers, RMSSD, RRI-HF powers, and BRS increased after 1 h and rose to peak values occurring after 5, 1, 2, 2, 1, 4, 4, and 4 h, respectively. After 3 h, BPdia had decreased significantly and was lowest after 5 h. RRI-LF/HF ratios decreased to a nadir after 4 h. Conclusions: The increases in parasympathetic and overall cardiac autonomic modulation and in BRS seen with fingolimod initiation are theoretically beneficial for the MS patient’s cardiovascular system. However, long-term studies must show whether these effects persist or are attenuated (e.g. due to S1P1 receptor down-regulation upon continued fingolimod therapy).

Sign in / Sign up

Export Citation Format

Share Document